CRISPR-Edited Stem Cells in a Patient with HIV and Acute Lymphocytic Leukemia
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
disruption in lymphocytes was only approximately 5%, which indicates the need for further research into this approach. (Funded by the Beijing Municipal Science and Technology Commission and others; ClinicalTrials.gov number, NCT03164135.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Subsequent experiments showed that p53 inactivation can be controlled or avoided through protocol optimization 47,107 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [107]
Citations
Cites
1 retracted
CCR5-∆32 is deleterious in the homozygous state in humans
Wei, X., & Nielsen, R. (2019) · Nature Medicine · doi:10.1038/s41591-019-0459-6 · Cited by 75
RetractedIdentification of a major co-receptor for primary isolates of HIV-1
Deng, H., Liu, R., Ellmeier, W., Choe, S., Unutmaz, D., Burkhart, M., Marzio, P. D., Marmon, S., Sutton, R. E., Hill, C. M., et al. (1996) · Nature · doi:10.1038/381661a0 · Cited by 3,641
Self-citationSamson, M., Libert, F., Doranz, B. J., Rucker, J., Liesnard, C., Farber, C.-M., Saragosti, S., Lapouméroulie, C., Cognaux, J., Forceille, C., et al. (1996) · Nature · doi:10.1038/382722a0 · Cited by 2,886
A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency
Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., McIntyre, E., Radford, I., Villeval, J.-L., Fraser, C. C., Cavazzana-Calvo, M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejm200301163480314 · Cited by 1,867
Long-Term Control of HIV by CCR5 Delta32/Delta32 Stem-Cell Transplantation
Hütter, G., Nowak, D., Mossner, M., Ganepola, S., Müßig, A., Allers, K., Schneider, T., Hofmann, J., Kücherer, C., Blau, O., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0802905 · Cited by 1,837
Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV
Tebas, P., Stein, D., Tang, W. W., Frank, I., Wang, S. Q., Lee, G., Spratt, S. K., Surosky, R. T., Giedlin, M. A., Nichol, G., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300662 · Cited by 1,357
CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes
Komor, A. C., Badran, A. H., & Liu, D. R. (2017) · Cell · doi:10.1016/j.cell.2016.10.044 · Cited by 1,013
Gene Therapy for Immunodeficiency Due to Adenosine Deaminase Deficiency
Aiuti, A., Cattaneo, F., Galimberti, S., Benninghoff, U., Cassani, B., Callegaro, L., Scaramuzza, S., Andolfi, G., Mirolo, M., Brigida, I., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805817 · Cited by 1,007
Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases
Perez, E. E., Wang, J., Miller, J. C., Jouvenot, Y., Kim, K. A., Liu, O., Wang, N., Lee, G., Bartsevich, V. V., Lee, Y.-L., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1410 · Cited by 999
Self-citationCRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells
Dever, D. P., Bak, R. O., Reinisch, A., Camarena, J., Washington, G., Nicolas, C. E., Pavel-Dinu, M., Saxena, N., Wilkens, A. B., Mantri, S., et al. (2016) · Nature · doi:10.1038/nature20134 · Cited by 864
Cited by
Li, H., Yang, Y., Hong, W., Huang, M., Wu, M., & Zhao, X. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0089-y · Cited by 1,715
“A recently reported article showed that Chinese scientists have established a CRISPR/Cas9modified CCR5 gene editing system for adult HPSCs to achieve long-term and stable hematopoietic system reconstruction after infusion of modified CD34+ cells into patients with HIV-1 infection and ALL (NCT03164135).(271) This study…”
BackgroundCRISPR-engineered T cells in patients with refractory cancer
Stadtmauer, E. A., Fraietta, J. A., Davis, M. M., Cohen, A. D., Weber, K. L., Lancaster, E., Mangan, P. A., Kulikovskaya, I., Gupta, M., Chen, F., et al. (2020) · Science · doi:10.1126/science.aba7365 · Cited by 1,478
“The first pilot human trials using genome editing were conducted in patients with HIV/AIDS and targeted the white blood cell protein CCR5, with the goal of mutating the CCR5 gene by nonhomologous recombination and thereby inducing resistance to HIV infection (3, 4).”
BackgroundSelf-citationThe evolution of commercial drug delivery technologies
Vargason, A. M., Anselmo, A. C., & Mitragotri, S. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00698-w · Cited by 1,361
The promise and challenge of therapeutic genome editing
Doudna, J. A. (2020) · Nature · doi:10.1038/s41586-020-1978-5 · Cited by 1,126
Lu, Y., Xue, J., Deng, T., Zhou, X., Yu, K., Deng, L., Huang, M., Yi, X., Liang, M., Wang, Y., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0840-5 · Cited by 539
Self-citationCRISPR-Based Therapeutic Genome Editing: Strategies and In Vivo Delivery by AAV Vectors
Wang, D., Zhang, F., & Gao, G. (2020) · Cell · doi:10.1016/j.cell.2020.03.023 · Cited by 527
CCL5/CCR5 axis in human diseases and related treatments
Zeng, Z., Lan, T., Wei, Y., & Wei, X. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2021.08.004 · Cited by 378
“At present, there are lots of techniques that can be implemented into the therapies against such diseases, like zinc finger nuclease (ZFN), TALEN, 185 ribozyme, 186 shRNA 187 and CRISPR/Cas9.”
InfluentialThe once and future gene therapy
Bulaklak, K., & Gersbach, C. A. (2020) · Nature Communications · doi:10.1038/s41467-020-19505-2 · Cited by 321
CRISPR-Cas9: A Preclinical and Clinical Perspective for the Treatment of Human Diseases
Sharma, G., Sharma, A. R., Bhattacharya, M., Lee, S.-S., & Chakraborty, C. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.09.028 · Cited by 283
“The study suggested the need for increasing the efficiency of CCR5 disruption in lymphocytes.(184)”
BackgroundHu, Y., Zhou, Y., Zhang, M., Ge, W., Li, Y., Yang, L., Wei, G., Han, L., Wang, H., Yu, S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3863 · Cited by 280
CRISPR technologies for genome, epigenome and transcriptome editing
Villiger, L., Joung, J., Koblan, L., Weissman, J., Abudayyeh, O. O., & Gootenberg, J. S. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00697-6 · Cited by 256
“This trial saw stable engraftment of edited cells, albeit with low levels of editing that were deemed insufficient for cure of HIV infection 304 .”
Delivery of CRISPR-Cas tools for in vivo genome editing therapy: Trends and challenges
Taha, E. A., Lee, J., & Hotta, A. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.013 · Cited by 259
Application of CRISPR-Cas9 genome editing technology in various fields: A review
Ansori, A. N., Antonius, Y., Susilo, R. J., Hayaza, S., Kharisma, V. D., Parikesit, A. A., Zainul, R., Jakhmola, V., Saklani, T., Rebezov, M., et al. (2023) · Narra J · doi:10.52225/narra.v3i2.184 · Cited by 208
“With further advancements, CRISPR-Cas9 holds promise for addressing unmet medical needs and improving patient outcomes [33].”
BackgroundGupta, R. K., Peppa, D., Hill, A. L., Gálvez, C., Salgado, M., Pace, M., McCoy, L. E., Griffith, S. A., Thornhill, J., Alrubayyi, A., et al. (2020) · The Lancet HIV · doi:10.1016/s2352-3018(20)30069-2 · Cited by 221
CRISPR-based genome editing through the lens of DNA repair
Nambiar, T. S., Baudrier, L., Billon, P., & Ciccia, A. (2022) · Molecular Cell · doi:10.1016/j.molcel.2021.12.026 · Cited by 208
Ottaviano, G., Georgiadis, C., Gkazi, S. A., Syed, F., Zhan, H., Etuk, A., Preece, R., Chu, J., Kubat, A., Adams, S., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abq3010 · Cited by 199
A review of emerging physical transfection methods for CRISPR/Cas9-mediated gene editing
Fajrial, A. K., He, Q. Q., Wirusanti, N. I., Slansky, J. E., & Ding, X. (2020) · Theranostics · doi:10.7150/thno.43465 · Cited by 185
“reported a case study of ex vivo CRISPR-edited stem cell therapy via electroporation [76].”
BackgroundIn vivo CD8+ T cell CRISPR screening reveals control by Fli1 in infection and cancer
Chen, Z., Arai, E., Khan, O., Zhang, Z., Ngiow, S. F., He, Y., Huang, H., Manne, S., Cao, Z., Baxter, A. E., et al. (2021) · Cell · doi:10.1016/j.cell.2021.02.019 · Cited by 207
CRISPR-Cas Tools and Their Application in Genetic Engineering of Human Stem Cells and Organoids
Hendriks, D., Clevers, H., & Artegiani, B. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2020.10.014 · Cited by 192
Applications and challenges of CRISPR-Cas gene-editing to disease treatment in clinics
Liu, W., Li, L., Jiang, J., Wu, M., & Lin, P. (2021) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbab014 · Cited by 175
In vivo somatic cell base editing and prime editing
Newby, G. A., & Liu, D. R. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.09.002 · Cited by 199
Li, C., Brant, E., Budak, H., & Zhang, B. (2021) · Journal of Zhejiang University-SCIENCE B · doi:10.1631/jzus.b2100009 · Cited by 177
“Their re‐ sults showed that the CRISPR/Cas-edited donor cells persisted for more than 19 months after transplantation without causing gene-editing-related adverse events (Xu et al., 2019; He, 2020).”
BackgroundSelf-citationRasul, M. F., Hussen, B. M., Salihi, A., Ismael, B. S., Jalal, P. J., Zanichelli, A., Jamali, E., Baniahmad, A., Ghafouri-Fard, S., Basiri, A., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01487-4 · Cited by 171
Applications of synthetic biology in medical and pharmaceutical fields
Yan, X., Liu, X., Zhao, C., & Chen, G.-Q. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01440-5 · Cited by 179
Fu, Y.-W., Dai, X.-Y., Wang, W.-T., Yang, Z.-X., Zhao, J.-J., Zhang, J.-P., Wen, W., Zhang, F., Oberg, K. C., Zhang, L., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkaa1251 · Cited by 180
“CRISPR-edited hematopoietic stem cells have been used in clinical trials to treat multiple disorders, such as AIDS (2) and hemoglobinopathies (3).”
BackgroundBio-Inspired Nanomaterials for Micro/Nanodevices: A New Era in Biomedical Applications
Harun‐Ur‐Rashid, M., Jahan, I., Foyez, T., & Imran, A. B. (2023) · Micromachines · doi:10.3390/mi14091786 · Cited by 185
Programmable base editing of mutated TERT promoter inhibits brain tumour growth
Li, X., Qian, X., Wang, B., Xia, Y., Zheng, Y., Du, L., Xu, D., Xing, D., DePinho, R. A., & Lu, Z. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0471-6 · Cited by 163
Enhancement of target specificity of CRISPR–Cas12a by using a chimeric DNA–RNA guide
Kim, H., Lee, W.-J., Oh, Y., Kang, S.-H., Hur, J. K., Lee, H., Song, W., Lim, K. S., Park, Y., Song, B., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa605 · Cited by 161
“This novel system is advantageous in terms of safety and has application potential for various purposes in vivo (22,23), and will eventually be useful for gene therapy for diseases caused by genetic defects.”
BackgroundImmunogenicity of CRISPR therapeutics—Critical considerations for clinical translation
Ewaisha, R., & Anderson, K. S. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1138596 · Cited by 165
“Unlike hereditary transthyretin amyloidosis in which knockout of mutated genes from only a proportion of hepatocytes can be sufficient for symptomatic treatment, HIV cure requires the complete elimination of HIV DNA from all cell reservoirs.”
BackgroundInfluentialCell‐Based Delivery Systems: Emerging Carriers for Immunotherapy
Li, Z., Wang, Y., Ding, Y., Repp, L., Kwon, G. S., & Hu, Q. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202100088 · Cited by 146
HIV-1 remission and possible cure in a woman after haplo-cord blood transplant
Hsu, J., Van Besien, K., Glesby, M. J., Pahwa, S., Coletti, A., Warshaw, M. G., Petz, L. D., Moore, T. B., Chen, Y. H., Pallikkuth, S., et al. (2023) · Cell · doi:10.1016/j.cell.2023.02.030 · Cited by 126
Khoshandam, M., Soltaninejad, H., Mousazadeh, M., Hamidieh, A. A., & Hosseinkhani, S. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.02.027 · Cited by 152
“The primary clinical trial on CRISPR-based ex vivo genome editing endeavored to treat human immunodeficiency virus 1 (HIV-1) infection.(32) Disruption of CCR5, which encodes a critical receptor for the viral compartment, was initiated by nucleofection of CCR5-centered ribonucleoprotein complexes in patient-derived hem…”
BackgroundThe NIH Somatic Cell Genome Editing program
The SCGE Consortium, Saha, K., Sontheimer, E. J., Brooks, P. J., Dwinell, M. R., Gersbach, C. A., Liu, D. R., Murray, S. A., Tsai, S. Q., Wilson, R. C., et al. (2021) · Nature · doi:10.1038/s41586-021-03191-1 · Cited by 125
CRISPR/Cas-Based Epigenome Editing: Advances, Applications, and Clinical Utility
Goell, J., & Hilton, I. B. (2021) · Trends in biotechnology · doi:10.1016/j.tibtech.2020.10.012 · Cited by 136
Human genetic diversity alters off-target outcomes of therapeutic gene editing
Cancellieri, S., Zeng, J., Lin, L. Y., Tognon, M., Nguyen, M. A., Lin, J., Bombieri, N., Maitland, S. A., Ciuculescu, M.-F., Katta, V., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01257-y · Cited by 133
Cancer biomarkers for targeted therapy
Liu, D. (2019) · Biomarker Research · doi:10.1186/s40364-019-0178-7 · Cited by 120
Gene therapy: a double-edged sword with great powers
Tang, R., & Xu, Z. (2020) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-020-03834-3 · Cited by 134
Liu, B., Zhang, W., Xia, B., Jing, S., Du, Y., Zou, F., Li, R., Lu, L., Chen, S., Li, Y., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci150211 · Cited by 106
Self-citationTebas, P., Jadlowsky, J. K., Shaw, P. A., Tian, L., Esparza, E., Brennan, A. L., Kim, S., Naing, S. Y., Richardson, M. W., Vogel, A. N., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci144486 · Cited by 99
“Other gene-editing methods including CRISPR are also in development for HIV (44).”
MethodMashel, T. V., Tarakanchikova, Y. V., Muslimov, A. R., Zyuzin, M. V., Timin, A. S., Lepik, K. V., & Fehse, B. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120282 · Cited by 105
CRISPR/Cas systems: Delivery and application in gene therapy
Huang, J., Zhou, Y., Li, J., Lü, A., & Liang, C. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.942325 · Cited by 116
CRISPR-Cas13 System as a Promising and Versatile Tool for Cancer Diagnosis, Therapy, and Research
Palaz, F., Kalkan, A. K., Can, Ö., Demir, A. N., Tozluyurt, A., Özcan, A., & Özsöz, M. (2021) · ACS Synthetic Biology · doi:10.1021/acssynbio.1c00107 · Cited by 110
Block-And-Lock: New Horizons for a Cure for HIV-1
Moranguinho, I., & Valente, S. T. (2020) · Viruses · doi:10.3390/v12121443 · Cited by 105
“Of note, no apparent clinical adverse or off-target effects were reported; however, CCR5 ablation was less than 8% in the genome of circulating bone marrow cells [181].”
BackgroundComprehensive assessment of miniature CRISPR-Cas12f nucleases for gene disruption
Xin, C., Yin, J., Yuan, S., Ou, L., Liu, M., Zhang, W., & Hu, J. (2022) · Nature Communications · doi:10.1038/s41467-022-33346-1 · Cited by 110
Recent advances in the delivery and applications of nonviral CRISPR/Cas9 gene editing
Sinclair, F., Begum, A. A., Dai, C. C., Tóth, I., & Moyle, P. M. (2023) · Drug Delivery and Translational Research · doi:10.1007/s13346-023-01320-z · Cited by 104
Frequency and mechanisms of LINE-1 retrotransposon insertions at CRISPR/Cas9 sites
Tao, J., Wang, Q., Mendez‐Dorantes, C., Burns, K. H., & Chiarle, R. (2022) · Nature Communications · doi:10.1038/s41467-022-31322-3 · Cited by 96
Liang, J., Teng, P., Xiao, W., He, G., Song, Q., Zhang, Y., Peng, B., Li, G., Hu, L., Cao, D., et al. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-01021-0 · Cited by 88
Self-citationAllen, D. G., Rosenberg, M., & Hendel, A. (2021) · Frontiers in Genome Editing · doi:10.3389/fgeed.2020.617910 · Cited by 95
Current approaches in CRISPR-Cas9 mediated gene editing for biomedical and therapeutic applications
Bhattacharjee, G., Gohil, N., Khambhati, K., Mani, I., Maurya, R., Karapurkar, J. K., Gohil, J., Chu, D., Vu‐Thi, H., Alzahrani, K. J., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.02.005 · Cited by 96
Cromer, M. K., Camarena, J., Martin, R. M., Lesch, B. J., Vakulskas, C. A., Bode, N. M., Kurgan, G., Collingwood, M. A., Rettig, G. R., Behlke, M. A., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01284-y · Cited by 82
Self-citationCRISPR Therapeutics for Duchenne Muscular Dystrophy
Erkut, E. J. N., & Yokota, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031832 · Cited by 96
“Since its first discovery in 1987, and subsequent first use in vivo in 2013 [61], CRISPR has been applied to numerous diseases and has even moved forward to clinical trials in some cases [62,63] (Figure 2).”
BackgroundTargeting CCR5 as a Component of an HIV-1 Therapeutic Strategy
Mohamed, H., Gurrola, T., Berman, R., Collins, M., Sariyer, I. K., Nonnemacher, M. R., & Wigdahl, B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.816515 · Cited by 81
Detect and destroy: CRISPR-based technologies for the response against viruses
Freije, C. A., & Sabeti, P. C. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.04.003 · Cited by 83
“However, transplantation was not sufficient to cure the patient of infection (Xu et al., 2019).”
The clinical potential of gene editing as a tool to engineer cell‐based therapeutics
Ashmore‐Harris, C., & Fruhwirth, G. O. (2020) · Clinical and Translational Medicine · doi:10.1186/s40169-020-0268-z · Cited by 79
CRISPR-Cas System: An Approach With Potentials for COVID-19 Diagnosis and Therapeutics
Kumar, P., Malik, Y. S., Ganesh, B., Rahangdale, S., Saurabh, S., Natesan, S. K. A., Srivastava, A., Sharun, K., Yatoo, M. I., Tiwari, R., et al. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.576875 · Cited by 83
Xu, H., Lin, S., Zhou, Z., Li, D., Zhang, X., Yu, M., Zhao, R., Wang, Y., Qian, J., Li, X., et al. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01032-x · Cited by 83
Self-citationReactivation of γ-globin expression through Cas9 or base editor to treat β-hemoglobinopathies
Wang, L., Li, L., Ma, Y., Hu, H., Li, Q., Yang, Y., Liu, W., Yin, S., Li, W., Fu, B., et al. (2020) · Cell Research · doi:10.1038/s41422-019-0267-z · Cited by 82
Self-citationGene Editing by Extracellular Vesicles
Kostyushev, D. S., Kostyusheva, A. P., Brezgin, S. A., Vv, S., Volchkova, E. V., Lukashev, A. N., & Chulanov, V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197362 · Cited by 78
“The authors created a construct harboring a Psi (Ψ+) sequence that interacts with the endogenously produced HIV Gag protein to package sgRNA into exosomes [201].”
BackgroundInfluentialShapiro, J., Iancu, O., Jacobi, A. M., McNeill, M. S., Turk, R., Rettig, G. R., Amit, I., Tovin-Recht, A., Yakhini, Z., Behlke, M. A., et al. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.04.027 · Cited by 70
“17 June 2020 frequencies that were achieved in this study using conditions that are clinically relevant might eliminate the need for selection strategies, such as in the case of gene knockout of the C-C chemokine receptor type 5 (CCR5) gene, which encodes a co-receptor of HIV and is currently being investigated as a t…”
BackgroundAdvances in Developing CAR T-Cell Therapy for HIV Cure
Qi, J., Ding, C., Jiang, X. L., & Gao, Y. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00361 · Cited by 79
“reported successful transplantation and long-term engraftment of CRISPR/Cas9edited, CCR5-ablated HSPCs in a patient with HIV infection and acute lymphoblastic leukemia (49).”
BackgroundEvolving AAV-delivered therapeutics towards ultimate cures
He, X., Urip, B. A., Zhang, Z., Ngan, C. C., & Feng, B. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-020-02034-2 · Cited by 72
Immunological barriers to haematopoietic stem cell gene therapy
Charlesworth, C. T., Hsu, I., Wilkinson, A. C., & Nakauchi, H. (2022) · Nature reviews. Immunology · doi:10.1038/s41577-022-00698-0 · Cited by 74
HIV Persistence, Latency, and Cure Approaches: Where Are We Now?
Chou, T. C., Maggirwar, N. S., & Marsden, M. D. (2024) · Viruses · doi:10.3390/v16071163 · Cited by 86
“Though allogeneic stem cell reinfusion has been demonstrated [193], developing autologous transplantation approaches may be necessary to avoid graft incompatibility and difficulties associated with finding appropriate HIV-resistant stem cell donors.”
BackgroundEvolution of CRISPR/Cas Systems for Precise Genome Editing
Hryhorowicz, M., Lipiński, D., & Zeyland, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814233 · Cited by 79
“However, the efficiency of the response was not adequate to achieve the target of a cure for HIV-1 infection [54].”
Which long noncoding RNAs and circular RNAs contribute to inflammatory bowel disease?
Lin, L., Zhou, G., Chen, P., Wang, Y., Han, J., Chen, M., He, Y., & Zhang, S. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2657-z · Cited by 71
Gene editing and its applications in biomedicine
Li, G., Li, X., Zhuang, S., Wang, L., Zhu, Y., Chen, Y., Sun, W. C., Wu, Z., Zhou, Z. L., Chen, J., et al. (2022) · Science China Life Sciences · doi:10.1007/s11427-021-2057-0 · Cited by 77
“Clinical trials using ZNFs (NCT02500849) and CRISPR/ Cas9 (NCT03164135) to disrupt CCR5 in CD34 HSPCs have also been reported (Xu et al., 2019).”
BackgroundSelf-citationSniper2L is a high-fidelity Cas9 variant with high activity
Kim, Y.-H., Kim, N., Okafor, I. C., Choi, S.-C., Min, S., Lee, J., Bae, S.-M., Choi, K., Choi, J., Harihar, V., et al. (2023) · Nature Chemical Biology · doi:10.1038/s41589-023-01279-5 · Cited by 74
Chronic inflammation mediates brain injury in HIV infection: relevance for cure strategies
McArthur, J. C., & Johnson, T. P. (2020) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000807 · Cited by 70
Cas9-directed immune tolerance in humans—a model to evaluate regulatory T cells in gene therapy?
Wagner, D. L., Peter, L., & Schmueck-Henneresse, M. (2021) · Gene Therapy · doi:10.1038/s41434-021-00232-2 · Cited by 63
The power and the promise of CRISPR/Cas9 genome editing for clinical application with gene therapy
Guo, N., Liu, J., Li, W., Ma, Y., & Fu, D. (2021) · Journal of Advanced Research · doi:10.1016/j.jare.2021.11.018 · Cited by 70
“Acquired immunodeficiency syndrome (AIDS) is an untreatable disease caused by human immunodeficiency virus infection (HIV).”
BackgroundInfluentialThe Role of Recombinant AAV in Precise Genome Editing
Bijlani, S., Pang, K. M., Sivanandam, V., Singh, A., & Chatterjee, S. (2022) · Frontiers in Genome Editing · doi:10.3389/fgeed.2021.799722 · Cited by 68
“Ex vivo editing followed by infusion was found to be safe, although the level of edited cells was low in both studies (Tebas et al., 2014; Xu et al., 2019).”
ResultIn vivo CRISPR gene editing in patients with herpetic stromal keratitis
Wei, A., Yin, D., Zhai, Z., Ling, S., Le, H., Tian, L., Xu, J., Paludan, S. R., Cai, Y., & Hong, J. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.08.021 · Cited by 67
Self-citationCRISPR-Cas9 Mediated Exonic Disruption for HIV-1 Elimination
Herskovitz, J., Hasan, M., Patel, M., Blomberg, W. R., Cohen, J. D., Machhi, J., Stein, D., Schroder, E. A., McMillan, J., Gurumurthy, C. B., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103678 · Cited by 66
“Current ex vivo approaches ablate the HIV-1 co-receptor CCR5 with CRISPR-transducing lentiviruses [39,40].”
BackgroundThe future of stem cell therapies of Alzheimer’s disease
Wang, Z., Wang, Z.-T., Sun, Y., Tan, L., & Yu, J. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101655 · Cited by 68
An Update on the Application of CRISPR Technology in Clinical Practice
Morshedzadeh, F., Ghanei, M., Lotfi, M., Ghasemi, M., Ahmadi, M., Najari-Hanjani, P., Sharif, S., Mozaffari‐Jovin, S., Peymani, M., & Abbaszadegan, M. R. (2023) · Molecular Biotechnology · doi:10.1007/s12033-023-00724-z · Cited by 71
“28% in the bone marrow, it has been reported that no off-target effect occurred [73].”
Delivery Approaches for Therapeutic Genome Editing and Challenges
Ates, I., Rathbone, T., Stuart, C., Bridges, P. H., & Cottle, R. N. (2020) · Genes · doi:10.3390/genes11101113 · Cited by 63
Current trends of clinical trials involving CRISPR/Cas systems
Zhang, S., Wang, Y., Mao, D., Wang, Y., Zhang, H., Pan, Y., Wang, Y., Teng, S., & Huang, P. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1292452 · Cited by 70
“In addition, after HSPC transplantation, the peripheral blood CD4 + T cells recovered to their normal range by month 6, and the acute lymphoblastic leukemia was in complete remission for 19 months, even though CCR5 editing efficiency in bone marrow cells was less than 8.28% (151).”
BackgroundInfluentialProgress and challenges towards CRISPR/Cas clinical translation
Rosenblum, D., Gutkin, A., Dammes, N., & Peer, D. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.004 · Cited by 63
ON-Target Adverse Events of CRISPR-Cas9 Nuclease: More Chaotic than Expected
Boutin, J., Cappellen, D., Rosier, J., Amintas, S., Dabernat, S., Bedel, A., & Moreau‐Gaudry, F. (2022) · The CRISPR Journal · doi:10.1089/crispr.2021.0120 · Cited by 68
Masarwy, R., Stotsky‐Oterin, L., Elisha, A., Hazan‐Halevy, I., & Peer, D. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115359 · Cited by 61
Targeting the undruggable oncogenic KRAS: the dawn of hope
Asimgil, H., Ertetik, U., Çevik, N. C., Ekizce, M., Doğruöz, A., Gökalp, M., Sever, E. A., Istvánffy, R., Friess, H., Ceyhan, G. O., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.153688 · Cited by 66
“corroborated the findings of another clinical study (48), supporting this method as a means of safe and feasible treatment.”
Wang, T., Zhang, J., Liao, J., Zhang, F., & Zhou, G. (2020) · Stem Cells Translational Medicine · doi:10.1002/sctm.20-0155 · Cited by 64
“Ten years later, a second individual (the “London patient”) with HIV-1 infection and concomitant leukemia was cured by allogeneic HSCT with stem cells bearing the CCR5Δ32/Δ32 mutation.48 With the aim of mimicing these results while avoiding ethics and safety issues, the CRISPR/ Cas9 gene editing technology was recentl…”
MethodOu, X., Ma, Q., Yin, W., Ma, X., & He, Z. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.674467 · Cited by 64
Du, Y., Ji, S., Dong, Q., Wang, J., Han, D., & Gao, Z. (2023) · Analytica Chimica Acta · doi:10.1016/j.aca.2023.340864 · Cited by 56
Self-citationHarris, A. R., Walker, M. J., & Gilbert, F. (2022) · BMC Medicine · doi:10.1186/s12916-022-02710-9 · Cited by 62
Adenovirus vectors in hematopoietic stem cell genome editing
Li, C., & Lieber, A. (2019) · FEBS Letters · doi:10.1002/1873-3468.13668 · Cited by 58
Self-citationRathore, A. S., Iketani, S., Wang, P., Jia, M., Sahi, V., & Ho, D. D. (2020) · Scientific Reports · doi:10.1038/s41598-020-62375-3 · Cited by 55
Knipping, F., Newby, G. A., Eide, C. R., McElroy, A. N., Nielsen, S. C., Smith, K. D., Fang, Y., Cornu, T. I., Costa, C., Gutiérrez-Guerrero, A., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.10.026 · Cited by 58
CRISPR-based strategies in infectious disease diagnosis and therapy
Binnie, A., Fernandes, E., Almeida-Lousada, H., de Mello, R. A., & Castelo‐Branco, P. (2021) · Infection · doi:10.1007/s15010-020-01554-w · Cited by 64
“In 2019, a group from China reported the successful bone marrow transplantation of an HIV-1-positive patient with acute lymphocytic leukemia for whom the hematopoietic progenitor cells had been CCR5-ablated using CRISPR in order to prevent HIV infection [76].”
BackgroundGene Editing of Hematopoietic Stem Cells: Hopes and Hurdles Toward Clinical Translation
Ferrari, S., Vavassori, V., Canarutto, D., Jacob, A., Castiello, M. C., Omer, A., & Genovese, P. (2021) · Frontiers in Genome Editing · doi:10.3389/fgeed.2021.618378 · Cited by 57
“, the disruption of the CCR5 open reading frame in hematopoietic cells to confer resistance to HIV infection (Wang and Cannon, 2016; Xu et al., 2019); (ii) restoration of the correct reading frame: NHEJ-mediated indels can be exploited to restore the normal reading frame of a gene and thus correct frame-shift mutation…”
BackgroundVolodina, O., & Smirnikhina, S. (2024) · Molecular Biotechnology · doi:10.1007/s12033-024-01070-4 · Cited by 59
“The percentage of CCR5 disruption in lymphocytes was only ~ 5% [48].”
Antiviral treatment causes a unique mutational signature in cancers of transplantation recipients
de Kanter, J. K., Peci, F., Bertrums, E., Rosendahl Huber, A., van Leeuwen, A., van Roosmalen, M. J., Manders, F., Verheul, M., Oka, R., Brandsma, A. M., et al. (2021) · Cell Stem Cell · doi:10.1016/j.stem.2021.07.012 · Cited by 55
Stimulus-Responsive Smart Nanoparticles-Based CRISPR-Cas Delivery for Therapeutic Genome Editing
Naeem, M., Hoque, M. Z., Ovais, M., Basheer, C., & Ahmad, I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011300 · Cited by 56
“Severe sickle cell disease BCL11A gene I/II [21] β-thalassemia HBB I [22] Advanced esophageal cancer PD-1 II [23] Gastrointestinal epithelial cancer CISH II [24] Hematological malignancies CCR5 Not available [25] Solid tumors PD-1 and TCR Receptors I [26] Leber congenital amaurosis (LCA) Photoreceptors gene I [27] Her…”
BackgroundGenome editing in large animal models
Maynard, L. H., Humbert, O., Peterson, C. W., & Kiem, H. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.09.026 · Cited by 51
Nano/genetically engineered cells for immunotherapy
Shen, J., Zhou, Y., & Yin, L. (2024) · BMEMat · doi:10.1002/bmm2.12112 · Cited by 54
CRISPR/Cas technology as a promising weapon to combat viral infections
Escalona‐Noguero, C., López‐Valls, M., & Sot, B. (2021) · BioEssays · doi:10.1002/bies.202000315 · Cited by 49
“Cas9 has been used to prevent viral cell entry by knockingout the CCR5 and CXCR4 co-receptors[57,65,59,69,61,68,62] and also to”
BackgroundMethodVariability in Genome Editing Outcomes: Challenges for Research Reproducibility and Clinical Safety
Teboul, L., Hérault, Y., Wells, S. E., Qasim, W., & Pavlovic, G. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.03.015 · Cited by 53
“Although the therapeutic goal was not met, no issues of immune reaction or other adverse effects were reported.(66,67)”
Current strategies employed in the manipulation of gene expression for clinical purposes
Tsai, H., Pietrobon, V., Peng, M., Wang, S., Zhao, L., Marincola, F. M., & Cai, Q. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03747-3 · Cited by 53
Self-citationCRISPR-based strategies for targeted transgene knock-in and gene correction
Lau, C., Tin, C., & Suh, Y. (2020) · Faculty Reviews · doi:10.12703/r/9-20 · Cited by 51
CRISPR-Cas System: The Current and Emerging Translational Landscape
Bhokisham, N., Laudermilch, E., Traeger, L. L., Bonilla, T. D., Ruíz-Estévez, M., & Becker, J. R. (2023) · Cells · doi:10.3390/cells12081103 · Cited by 55
Metadata
- Authors
- Xu, L., Wang, J., Liu, Y., Xie, L., Su, B., Mou, D., Wang, L., Liu, T., Wang, X., Zhang, B., Zhao, L., Hu, L., Ning, H., Zhang, Y., Deng, K., Liu, L., Lu, X., Zhang, T., Xu, J., Li, C., Wu, H., Deng, H., & Chen, H.
- Affiliations
- Peking University (CN)
- Capital Medical University (CN)
- Sun Yat-sen University (CN)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-09-26
- Volume
- 381
- Issue
- 13
- Pages
- 1240-1247
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2972390440
- Cited by
- 454
- References
- 27
- Citations by year
- 2026: 34 · 2025: 52 · 2024: 57 · 2023: 45 · 2022: 77 · 2021: 87 · 2020: 89 · 2019: 13
- FWCI
- 21.99
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Key Research and Development Program of China (2017YFA0103000)
- Beijing Municipal Science and Technology Commission (D171100000517004)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- CRISPR gene editing, hematopoietic stem cells, HIV, acute lymphoblastic leukemia, gene therapy
- MeSH terms
- Gene Editing, Adult, Blood Cell Count, Hematopoietic Stem Cells, Humans, Male, HIV-1, HIV Infections, Hematopoietic Stem Cell Transplantation, CD4 Lymphocyte Count, Viral Load, Receptors, CCR5, Anti-Retroviral Agents, Precursor Cell Lymphoblastic Leukemia-Lymphoma, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.